---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-023908"
form_type: "8-K"
ticker: "ABEO"
cik: "0000318306"
company_name: "ABEONA THERAPEUTICS INC."
filed_at: "2023-07-07T23:59:59+00:00"
generated_at: "2026-06-13T11:20:53.833437+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Abeona closes $25M direct offering; proceeds to fund EB-101 commercialization

## Summary
- Gross proceeds of $25M from sale of 3.28M shares and 2.92M pre-funded warrants at $4.03 per share.
- Offering led by Nantahala Capital Management with participation by Adage Capital Partners and other existing investors.
- Net proceeds to fund commercialization of EB-101 and extend cash runway into Q4 2024.
- Company expects to qualify for a priority review voucher upon potential BLA approval in H1 2024.

## SEC filing metadata
- accession: 0001493152-23-023908
- form_type: 8-K
- ticker: ABEO
- cik: 0000318306
- company_name: ABEONA THERAPEUTICS INC.
- filed_at: 2023-07-07T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/318306/000149315223023908/0001493152-23-023908-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/318306/000149315223023908/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-023908
- JSON: https://secwatch.observer/filing/0001493152-23-023908.json
- Plain text: https://secwatch.observer/filing/0001493152-23-023908.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.